Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
The aim of this study is the safety and efficacy of Cetuximab plus natural killer(NK) immunotherapy to recurrent non-small cell lung cancer with EGFR mutation.
Recurrent Non-small Cell Lung Cancer
DRUG: Cetuximab|BIOLOGICAL: NK immunotherapy
Relief degree evaluated by RECIST, It will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST), 3 months
Progress free survival (PFS), 1 year|Overall survival (OS), 3 years
By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Cetuximab and NK cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).